Dicerna Pharmaceuticals

^{Priced, Nasdaq: DRNA}

Developing RNAi therapeutics for the treatment of rare liver disease and cancer.

Industry: Health Care

First Day Return: +206.7%

DRNA

Developing RNAi therapeutics for the treatment of rare liver disease and cancer.

IPO News for Dicerna Pharmaceuticals

More capital for Canadian cancer cures: ProNAi Therapeutics increases proposed IPO deal size by 37% 07/15/15
Canadian cancer biotech ProNAi Therapeutics sets terms for $101 million IPO 07/06/15
Something good out of Canada: Cancer biotech ProNAi Therapeutics files for an $86 million IPO 06/12/15

IPO Data
IPO Date	01/29/2014
Offer Price	IPO Intelligence Only
Price Range	IPO Intelligence Only
Offer Shares (mm)	IPO Intelligence Only
Deal Size ($mm)	$90
Lock-Up Date	IPO Intelligence Only
Street Research	IPO Intelligence Only

Underwriters
IPO Intelligence Only

Company Data
Website www.dicerna.com
Headquarters	Watertown, MA, United States
Founded	2006
Employees at IPO	24

IPO News for Dicerna Pharmaceuticals

Dicerna Pharmaceuticals (DRNA) Performance